BiomX Inc.PHGE

BiomX Inc. has spent the past month filing filing trail that reads like a corporate cry for help, topped off this week by its PRE 14A proxy statement filed on 17 July 2026. The document is a reminder that the company’s board is still ticking the regulatory boxes, even as the balance sheet quietly screams. The proxy itself is less a governance manifesto than a polite fiction, arriving alongside a 10-Q that shows the firm lost $19.1 million in the quarter ending March 2026 and now holds just $1.2 million in cash. The contrast between management desks theatrics and balance-sheet reality could not be sharper: the company’s net equity sits at negative $881,000, while its operating loss for the quarter was $1.3 million. If BiomX were a restaurant, the PRE 14A would be the glossy menu; the 10-Q would be the “out of business” sign in the window.

BiomX trades under the ticker PHGE on NYSE American, where the last reported share price was $0.3960 on 26 June 2026. The company’s 424B3 filing dated 14 July 2026 is a regulatory nudge reminding everyone that the shares still trade under that symbol, a move that feels less like investor communication and more like a desperate attempt to keep the ticker alive. The filing is emblematic of a firm that has spent years churning out filing trail while its cash and assets dwindle: total assets at 31 March 2026 stood at $3.3 million, while liabilities sat at $4.1 million. The company’s 8-K filings from 2 July and 10 July 2026 record minor corporate housekeeping-amendments to stockholders’ agreements and approval of a reverse stock split-moves that feel less like strategic decisions and more like survival tactics for a stock that has long since lost its narrative.

The firm’s financials are brutal but consistent. The 10-Q for the quarter ending 31 March 2026 shows net income (loss) attributable to parent of negative $19.1 million, operating income (loss) of negative $1.3 million, and cash and cash equivalents of $1.2 million. Net cash used in operating activities for the quarter was $5.4 million, while research and development expense for the year ending 31 December 2025 was $21.3 million. The company’s 10-K for 2025 notes just $2,000 spent on property, plant and equipment, a figure that underscores the firm’s asset-light, R&D-heavy model-and its lack of tangible infrastructure. Shareholder equity at 31 March 2026 was negative $881,000, and the weighted average number of shares outstanding, diluted, was 1.6 million as of the 2025 10-K. The numbers add up to a simple truth: BiomX is spending like a biotech outfit and earning like a charity.

The company’s filings are a ledger of regulatory compliance rather than operational progress. Its EFFECT filing from 13 July 2026 and its S-8 filing from 30 June 2026 are routine corporate actions with little market impact. The PRE 14A proxy statement, meanwhile, is a reminder that governance filing trail continues even when the business model is still searching for one. The firm’s attempts to keep the share price above water-including the reverse stock split approved in the 8-K filed 10 July 2026-are classic late-stage corporate manoeuvres, not evidence of a turnaround. The SEC submissions JSON and companyfacts JSON confirm the filing deluge but add no operational detail: the rail is thin, the evidence is consistent, and the tension is visible.

For a stock that trades on a major US exchange, BiomX’s public profile is unusually quiet. The company’s website and press releases are sparse, and the SEC filings are the primary window into its operations. The PRE 14A proxy is the latest instalment in a long series of filing trail-driven events; the 10-Q and 10-K filings are the real story. The company’s research tab, meanwhile, remains its single largest expense line, a fact that explains why the firm’s cash burn dwarfs its revenue. Until BiomX can translate its R&D spend into clinical or commercial progress, the filings will continue to read like a corporate holding pattern rather than a growth story.